KZIA.NASDAQKazia Therapeutics LTD
F-1: Kazia Therapeutics Registers ADSs for Resale by Investors
Sentiment:
Resale Registration Statement
Kazia Therapeutics Limited has filed to register 232,956 American Depositary Shares for resale by existing selling shareholders, with no direct proceeds to the company from these sales.
Capital raiseThe filing details the August 2025 Private Placement where the company issued 14,204,500 ordinary shares at $0.0176 per share and Pre-Funded Warrants to purchase up to 204,547 ADSs at $8.7999 per Pre-Funded Warrant.The company has an existing Equity Line of Credit (ELOC) agreement with Alumni Capital LP, allowing it to sell up to $15,000,000 of ADSs from time to time until December 31, 2025.The company has engaged in numerous ATM facility sales and other placements since January 2022, indicating a continuous need and strategy for capital raising.
Summary
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, has filed an F-1 registration statement for the resale of up to 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares, by certain selling shareholders.
- The company will not receive any proceeds from the sale of these Offered ADSs by the Selling Shareholders, though it may receive nominal proceeds (approximately $20.45) if all pre-funded warrants are exercised for cash.
- The ADSs are listed on the Nasdaq Capital Market under the symbol KZIA, with a last reported sale price of $7.47 per ADS on September 29, 2025.
- Kazia Therapeutics is developing paxalisib, a brain-penetrant inhibitor for glioblastoma and advanced breast cancer, and EVT801, a selective inhibitor for vascular endothelial growth factor receptor 3.
- The company has undertaken multiple capital raising activities since January 2022, including ATM facility sales, private placements, registered direct offerings, and equity line of credit facilities.
- As of December 31, 2024, the company reported actual cash and cash equivalents of $2,005,283 and a total equity deficit of $(2,740,475). Pro forma figures, reflecting subsequent capital raises, show cash and cash equivalents of $8,316,310 and total equity of $3,570,553.
- Kazia Therapeutics is a foreign private issuer, which allows for reduced public company reporting requirements compared to U.S. domestic companies.
Sentiment
Score: 5
Explanation: The filing is primarily procedural for the resale of previously issued securities. While it highlights recent capital raises that improved the pro forma financial position, it also reiterates ongoing Nasdaq listing compliance challenges (MVLS) and the company's PFIC status, balancing out the sentiment. No new positive or negative operational news is presented.
Positives
- The company has successfully raised significant capital through various offerings, including a pro forma cash and cash equivalents balance of $8,316,310 as of December 31, 2024, after accounting for subsequent financings.
- The pro forma total equity has shifted from a deficit of $(2,740,475) to a positive $3,570,553, indicating improved financial positioning from recent capital raises.
- Regained compliance with Nasdaq's minimum bid price requirement on November 12, 2024, following an ADS ratio change.
Negatives
- The company will not receive any proceeds from the resale of the 232,956 ADSs by the Selling Shareholders, limiting direct capital infusion from this specific registration.
- The company received a notification on May 12, 2025, that its Market Value of Listed Securities (MVLS) was below Nasdaq's minimum $35 million requirement, posing a risk of delisting if not remedied by November 10, 2025.
- The company has a history of significant accumulated losses, with $(81,857,706) as of December 31, 2024.
- The company believes it was a Passive Foreign Investment Company (PFIC) for the 2023 taxable year, which can have adverse U.S. federal income tax consequences for U.S. holders.
Risks
- The market price of the ADSs has been and will likely continue to be volatile, potentially leading to a loss of investment.
- If the ADS market price falls and remains below $5.00 per share, shareholders may be unable to use ADSs as collateral for margin accounts, potentially depressing demand and increasing volatility.
- Failure to meet Nasdaq's continued listing requirements, specifically the Market Value of Listed Securities (MVLS) requirement, could lead to delisting and severely limit liquidity.
- Raising additional capital in the future may cause dilution to existing shareholders, restrict operations, or require relinquishing valuable intellectual property rights.
- Future sales or issuances of ADSs or other equity-related securities could depress the trading price of the ADSs.
- ADS holders are reliant on the Depositary for exercising voting rights and receiving distributions, which may result in delays or inability to exercise these rights.
- The company does not currently intend to pay dividends, meaning investment returns depend solely on ADS price appreciation, which is not guaranteed.
- Unacceptable toxicity findings or lack of efficacy in clinical trials for product candidates (e.g., paxalisib, EVT801) could materially affect the business.
- Changes in economic conditions in Australia, the U.S., EU, or globally could adversely impact the company's ability to grow profitably.
- The company's PFIC status for U.S. federal income tax purposes is complex and subject to annual determination, potentially leading to adverse tax consequences for U.S. holders.
Future Outlook
The company plans to develop and potentially commercialize its product candidates, including paxalisib and EVT801. This involves initiating and completing preclinical studies and clinical trials, patient enrollment and dosing, and achieving regulatory approvals. Management anticipates ongoing expenses and losses, with future revenue and capital needs, and expects its current cash and cash equivalents to be sufficient for a certain period. The company also aims to strengthen its intellectual property position.
Industry Context
Kazia Therapeutics operates in the highly competitive and rapidly changing oncology-focused biotechnology sector. Its lead candidate, paxalisib, targets glioblastoma, a severe form of brain tumor, and advanced breast cancer, indicating a focus on high-unmet-need areas. The development of EVT801, a selective inhibitor of VEGFR3, positions the company in the vascular endothelial growth factor pathway, a common target in cancer therapy. The company's status as a foreign private issuer allows for reduced reporting, which is common for international biotech firms seeking to list on U.S. exchanges, but may also affect investor perception due to less frequent disclosures compared to domestic peers.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Vice President, Finance and Controller | NA | Jeffrey Bonacorda | April 25, 2024 | New employment agreement. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | The filing describes the company's Constitution, which governs corporate affairs, including director compensation, borrowing powers, retirement of directors, dividend rights, voting rights, and procedures for share capital changes. No specific changes to these governance structures are detailed in this filing, but rather a summary of existing provisions. | NA | NA |
Related Party Transactions
- Alumni Capital LP is a Selling Shareholder and has an Equity Line of Credit (ELOC) Purchase Agreement with the company, allowing the company to sell up to $15,000,000 of ADSs to Alumni Capital LP from time to time.
- Alumni Capital LP also participated in the January 2025 Registered Direct Offering and Concurrent Private Placement, acquiring ADSs and warrants.
Stakeholder Impact
- Shareholders face potential dilution from past and future capital raises, as well as the resale of shares by selling shareholders.
- Shareholders are exposed to the risk of Nasdaq delisting if the company fails to meet the MVLS requirement, which could severely impact liquidity.
- U.S. holders of ADSs may face complex U.S. federal income tax consequences due to the company's potential PFIC status.
- Investors should be aware that the company does not intend to pay dividends, meaning returns are dependent on share price appreciation.
Next Steps
- The company will continue to monitor its Market Value of Listed Securities (MVLS) and take measures to regain compliance with Nasdaq's $35 million MVLS requirement by November 10, 2025.
- The company will continue to develop and potentially commercialize its product candidates, paxalisib and EVT801, through preclinical studies and clinical trials.
- The company will continue to make available information for U.S. holders to make a QEF election if it remains a PFIC.
Key Dates
| Date | Description |
|---|---|
| 2022-02-01 | Issued 500,000 options at A$0.94 per option to employees. |
| 2022-02-01 | Issued 800,000 options at A$0.94 per option to employees. |
| 2022-04-21 | Announced completion of phase II paxalisib trial to ASX. |
| 2022-05-05 | Issued 1,855,357 ordinary shares due to conversion of Triaxial convertible note. |
| 2022-05-24 | Issued 100,000 options at A$0.78 per option to employees. |
| 2022-05-24 | Issued 10,000 ordinary shares at A$0.826 per share under ATM facility. |
| 2022-06-02 | Issued 10,000 ordinary shares at A$0.802 per share under ATM facility. |
| 2022-06-06 | Issued 88,710 ordinary shares at A$0.837 per share under ATM facility. |
| 2022-06-09 | Issued 603,500 ordinary shares at A$0.84 per share under ATM facility. |
| 2022-06-14 | Issued 75,940 ordinary shares at A$0.824 per share under ATM facility. |
| 2022-06-15 | Issued 2,000 ordinary shares at A$0.83 per share under ATM facility. |
| 2022-06-20 | Issued 4,072,660 ordinary shares at A$0.869 per share under ATM facility. |
| 2022-07-07 | Issued 573,370 ordinary shares at A$0.7102 per share under ATM facility. |
| 2022-08-08 | Issued 8,561,490 ordinary shares at A$0.3316 per share under ATM facility. |
| 2022-08-09 | Issued 10,000 ordinary shares at A$0.2723 per share under ATM facility. |
| 2022-08-10 | Issued 158,020 ordinary shares at A$0.2465 per share under ATM facility. |
| 2022-08-11 | Issued 330,960 ordinary shares at A$0.2413 per share under ATM facility. |
| 2022-08-12 | Issued 1,247,440 ordinary shares at A$0.2469 per share under ATM facility. |
| 2022-09-12 | Issued 651,030 ordinary shares at A$0.2211 per share under ATM facility. |
| 2022-09-13 | Issued 28,350 ordinary shares at A$0.2187 per share under ATM facility. |
| 2022-09-14 | Issued 60,000 ordinary shares to the Scientific Advisory Board. |
| 2022-10-07 | Issued 736,760 ordinary shares at A$0.1789 per share under ATM facility. |
| 2022-10-28 | Issued 12,296,180 ordinary shares at A$0.1865 per share under ATM facility. |
| 2023-01-11 | Issued 20,000 ordinary shares at A$0.1380 per share under ATM facility. |
| 2023-01-16 | Issued 25,387,018 ordinary shares at A$0.11 per share in a professional and sophisticated investors placement. |
| 2023-02-28 | Issued 15,522,075 ordinary shares at A$0.11 per share in a professional and sophisticated investors placement. |
| 2023-03-03 | Issued 3,930,000 ordinary options at A$0.15 per option to employees. |
| 2023-03-03 | Issued 23,691,045 ordinary shares at A$0.11 per share in a share placement plan. |
| 2023-05-03 | Issued 4,000,000 ordinary options at A$0.187 per option to employees. |
| 2023-07-06 | Issued 8,148,140 ordinary shares at A$0.1856 per share under ATM facility. |
| 2023-07-07 | Issued 157,120 ordinary shares at A$0.1647 per share under ATM facility. |
| 2023-08-03 | Issued 15,000 ordinary shares at A$0.1679 per share under ATM facility. |
| 2023-11-20 | Received Nasdaq notice for bid price below $1.00. |
| 2023-11-29 | Issued 1,066,070 ordinary shares at A$0.1006 per share under ATM facility. |
| 2023-11-30 | Entered into Securities Purchase Agreement with an institutional investor for a registered direct offering and concurrent private placement. |
| 2023-12-05 | Issued 26,200,000 ordinary shares in ADSs at US$0.45 per ADS and pre-funded warrants to purchase up to 1,824,445 ADSs at US$0.44 per pre-funded warrant in a registered direct offering. |
| 2023-12-05 | Issued unregistered warrants to purchase up to 4,444,445 ADSs at US$0.583 per ADS in a private placement. |
| 2023-12-05 | Issued placement agent warrants to purchase up to 311,111 ADSs at US$0.5625 per ADS. |
| 2024-02-13 | Issued 25,910 ordinary shares at A$0.0466 per share under ATM facility. |
| 2024-02-14 | Issued 319,650 ordinary shares at A$0.0464 per share under ATM facility. |
| 2024-02-15 | Issued 2,195,980 ordinary shares at A$0.0468 per share under ATM facility. |
| 2024-02-18 | Issued 205,260 ordinary shares at A$0.0614 per share under ATM facility. |
| 2024-02-21 | Issued 18,244,450 ordinary shares in ADSs at US$0.01 per ADS in connection with a warrant exercise. |
| 2024-02-21 | Issued 8,626,580 ordinary shares at A$0.0595 per share under ATM facility. |
| 2024-02-22 | Issued 316,540 ordinary shares at A$0.0461 per share under ATM facility. |
| 2024-02-25 | Issued 304,860 ordinary shares at A$0.0464 per share under ATM facility. |
| 2024-02-26 | Issued 250,000 ordinary shares at A$0.0460 per share under ATM facility. |
| 2024-04-19 | Entered into a purchase agreement with Alumni Capital LP for an Equity Line of Credit (ELOC) of up to $15,000,000 and issued an Alumni Warrant. |
| 2024-04-25 | Jeffrey Bonacorda's employment agreement as VP, Finance and Controller became effective. |
| 2024-05-01 | Issued 2,112,560 ordinary shares at A$0.0478 per share under ATM facility. |
| 2024-05-02 | Issued 375,410 ordinary shares at A$0.0457 per share under ATM facility. |
| 2024-05-03 | Issued 288,900 ordinary shares at A$0.0469 per share under ATM facility. |
| 2024-05-07 | Issued 790,100 ordinary shares at A$0.0456 per share under ATM facility. |
| 2024-05-10 | Issued 20,000 ordinary shares at A$0.0455 per share under ATM facility. |
| 2024-05-12 | Received Nasdaq notification for MVLS below $35 million. |
| 2024-05-16 | Issued 242,170 ordinary shares at A$0.0450 per share under ATM facility. |
| 2024-05-17 | Investor agreed to waive a restriction in the November 30, 2023 Securities Purchase Agreement, and the company entered into a Warrant Amendment and New Warrant Issuance Agreement. |
| 2024-05-20 | Original deadline to regain Nasdaq minimum bid price compliance. |
| 2024-05-22 | Received Nasdaq letter granting an additional 180 calendar days to regain minimum bid price compliance. |
| 2024-05-29 | Filed registration statement on Form F-1 for resale of ADSs under the Alumni ELOC Purchase Agreement. |
| 2024-06-04 | Registration statement for Alumni ELOC Purchase Agreement declared effective by SEC. |
| 2024-06-19 | Issued 5,916,970 ordinary shares represented by 591,697 ADSs as repayment of a promissory note. |
| 2024-06-24 | Issued 29,000,000 ordinary shares at A$0.0268 per share under Equity Line of Credit facility. |
| 2024-06-24 | Alumni Capital purchased 2,900,000 ADSs at $0.178 per ADS under the Purchase Agreement. |
| 2024-07-11 | Investor exercised New Warrant to purchase 1,100,000 ADSs for $297,000. |
| 2024-07-11 | Issued 14,400,000 ordinary shares at A$0.1534 per share under ATM facility. |
| 2024-07-11 | Alumni Capital partially exercised Alumni Warrant to purchase 2,578,648 ADSs for $500,000. |
| 2024-07-12 | Issued 25,786,480 ordinary shares represented by 2,578,648 ADSs pursuant to a warrant exercise for US$0.1939 per ADSs. |
| 2024-07-12 | Issued 11,000,000 ordinary shares represented by 1,100,000 ADSs pursuant to a warrant exercise for US$0.27 per ADSs. |
| 2024-07-12 | Issued 5,488,230 ordinary shares at A$0.1445 per share under ATM facility. |
| 2024-07-17 | Issued 4,177,340 ordinary shares at A$0.1075 per share under ATM facility. |
| 2024-07-22 | Issued 15,000,000 ordinary shares at A$0.0542 per share under Equity Line of Credit facility. |
| 2024-07-22 | Alumni Capital purchased 1,500,000 ADSs at $0.361 per ADS under the Purchase Agreement. |
| 2024-08-08 | Issued 2,061,820 ordinary shares at A$0.0624 per share under ATM facility. |
| 2024-08-12 | Issued 408,270 ordinary shares at A$0.0641 per share under ATM facility. |
| 2024-08-13 | Issued 2,283,350 ordinary shares at A$0.0617 per share under ATM facility. |
| 2024-08-14 | Issued 8,660 ordinary shares at A$0.0606 per share under ATM facility. |
| 2024-08-27 | Issued 5,250,000 ordinary shares at A$0.0616 per share under ATM facility. |
| 2024-08-28 | Issued 308,700 ordinary shares at A$0.0591 per share under ATM facility. |
| 2024-08-30 | Issued 3,000,000 ordinary shares at A$0.0616 per share under ATM facility. |
| 2024-09-01 | Exchange rate of A$1.00 to US$0.6544 published by Reserve Bank of Australia. |
| 2024-09-03 | Issued 837,030 ordinary shares at A$0.0638 per share under ATM facility. |
| 2024-09-12 | Issued 16,049,020 ordinary shares at A$0.0554 per share under ATM facility. |
| 2024-09-13 | Issued 2,503,820 ordinary shares at A$0.0552 per share under ATM facility. |
| 2024-09-23 | Beneficial ownership of ADSs by selling shareholders calculated. |
| 2024-09-29 | Last reported sale price of ADSs on Nasdaq was $7.47 per ADS. |
| 2024-10-28 | Effected an ADS ratio change from 1:10 to 1:100 ordinary shares. |
| 2024-11-12 | Received written notification from Nasdaq confirming regained compliance with minimum bid price requirement. |
| 2024-11-15 | Filed Annual Report on Form 20-F for the year ended June 30, 2024. |
| 2024-11-18 | Deadline to regain Nasdaq minimum bid price compliance (extended period). |
| 2024-11-22 | Issued 442,400 ordinary shares at A$0.0891 per share under ATM facility. |
| 2024-11-25 | Issued 185,100 ordinary shares at A$0.0881 per share under ATM facility. |
| 2024-11-26 | Issued 262,200 ordinary shares at A$0.0848 per share under ATM facility. |
| 2024-11-27 | Issued 896,700 ordinary shares at A$0.0858 per share under ATM facility. |
| 2024-11-29 | Issued 364,700 ordinary shares at A$0.0818 per share under ATM facility. |
| 2024-12-02 | Issued 2,926,100 ordinary shares at A$0.0778 per share under ATM facility. |
| 2024-12-03 | Issued 403,300 ordinary shares at A$0.0787 per share under ATM facility. |
| 2024-12-04 | Issued 460,800 ordinary shares at A$0.0781 per share under ATM facility. |
| 2024-12-09 | Issued 142,200 ordinary shares at A$0.0665 per share under ATM facility. |
| 2024-12-10 | Issued 522,100 ordinary shares at A$0.0631 per share under ATM facility. |
| 2024-12-13 | Issued 15,000,000 ordinary shares at A$0.0537 per share under Equity Line of Credit facility. |
| 2024-12-13 | Alumni Capital purchased 150,000 ADSs at $3.411 per ADS under the Purchase Agreement. |
| 2024-12-16 | Issued 6,421,800 ordinary shares at A$0.0596 per share under ATM facility. |
| 2024-12-19 | Issued 20,000,000 ordinary shares at A$0.0437 per share under Equity Line of Credit facility. |
| 2024-12-19 | Alumni Capital purchased 200,000 ADSs at $2.708 per ADS under the Purchase Agreement. |
| 2024-12-31 | Issued 4,000,000 ordinary shares at A$0.0322 per share under ATM facility. |
| 2025-01-02 | Issued 2,939,500 ordinary shares at A$0.0292 per share under ATM facility. |
| 2025-01-03 | Issued 10,668,100 ordinary shares at A$0.0286 per share under ATM facility. |
| 2025-01-06 | Issued 2,453,900 ordinary shares at A$0.0289 per share under ATM facility. |
| 2025-01-10 | Entered into a securities purchase agreement with Alumni Capital LP for a registered direct offering and concurrent private placement. |
| 2025-01-13 | Closed registered direct offering, selling 553,440 ADSs and pre-funded warrants for 779,893 ADSs, and concurrent private placement of ordinary warrants for 1,333,333 ADSs. |
| 2025-01-14 | Issued 55,344,000 ordinary shares in ADSs at A$0.0242 per ADS and pre-funded warrants for 779,893 ADSs at US$1.4999 per pre-funded warrant in a registered direct offering. |
| 2025-01-14 | Issued unregistered Ordinary Warrants to purchase up to 1,333,333 ADSs and unregistered Placement Agent Warrants to purchase up to 40,000 ADSs. |
| 2025-01-30 | Filed registration statement on Form F-1 for resale of ADSs issuable upon exercise of Ordinary Warrants. |
| 2025-02-05 | Registration statement for resale of Ordinary Warrants ADSs declared effective by SEC. |
| 2025-02-06 | Issued 60,000,000 ordinary shares at A$0.0153 per share under Equity Line of Credit facility. |
| 2025-02-06 | Alumni Capital purchased 600,000 ADSs at $0.9595 per ADS under the Purchase Agreement. |
| 2025-03-28 | Start date of period where MVLS was below $35 million. |
| 2025-04-17 | Effected a second ADS ratio change from 1:100 to 1:500 ordinary shares. |
| 2025-05-01 | Issued 15,000,000 ordinary shares at A$0.0094 per share under Equity Line of Credit facility. |
| 2025-05-01 | Alumni Capital purchased 30,000 ADSs at $3.059 per ADS under the Purchase Agreement. |
| 2025-05-09 | End date of period where MVLS was below $35 million. |
| 2025-05-12 | Received Nasdaq notification for MVLS below $35 million. |
| 2025-06-05 | Issued 32,500,000 ordinary shares at A$0.01550 per share under Equity Line of Credit facility. |
| 2025-06-05 | Alumni Capital purchased 65,000 ADSs at $5.035 per ADS under the Purchase Agreement. |
| 2025-06-11 | Issued 35,000,000 ordinary shares at A$0.0280 per share under Equity Line of Credit facility. |
| 2025-06-11 | Alumni Capital purchased 70,000 ADSs at $9.063 per ADS under the Purchase Agreement. |
| 2025-06-17 | Issued 30,000,000 ordinary shares at A$0.0200 per share under Equity Line of Credit facility. |
| 2025-06-17 | Alumni Capital purchased 60,000 ADSs at $6.4315 per ADS under the Purchase Agreement. |
| 2025-07-25 | Issued 1,057,000 ordinary shares pursuant to partial cashless exercise of Placement Agent Warrants. |
| 2025-07-31 | Entered into Securities Purchase Agreements with Selling Shareholders for a private placement. |
| 2025-08-04 | Issued 14,204,500 ordinary shares at $0.0176 per share and Pre-Funded Warrants to purchase up to 204,547 ADSs at $8.7999 per Pre-Funded Warrant in a private placement. |
| 2025-08-19 | Issued 650,000 ordinary shares at A$0.0229 per share under ATM facility. |
| 2025-08-26 | Issued 1,382,500 ordinary shares at A$0.0255 per share under ATM facility. |
| 2025-08-31 | Company had 826,712,734 ordinary shares outstanding, 37,080,000 options, and 231,334,860 warrants outstanding. |
| 2025-09-11 | Issued 8,576,000 ordinary shares at A$0.0255 per share under ATM facility. |
| 2025-09-30 | Date of filing of the F-1 Registration Statement. |
| 2025-11-10 | Deadline to regain Nasdaq MVLS compliance. |
| 2025-12-31 | Termination date for the Alumni ELOC Purchase Agreement. |
Recommendation
holdThe filing is a procedural registration for the resale of shares by existing investors, not a new capital raise by the company for operational funding. While recent capital raises have improved the company's pro forma cash position and equity, the ongoing Nasdaq MVLS compliance issue and the company's historical accumulated losses present significant risks. The company's status as a PFIC for U.S. tax purposes also adds complexity for U.S. investors. Given the high degree of risk inherent in a clinical-stage biotech and the lack of new operational or financial performance data in this specific filing, a 'hold' recommendation is appropriate. Investors should await further clinical trial results and definitive resolution of listing compliance issues before considering a 'buy' or 'sell' position.
Keywords
Biotechnology, Oncology, Glioblastoma, Paxalisib, EVT801, SEC Filing, ADS, Nasdaq, Capital Raise, Risk Factors, Pharmaceutical, Clinical Trials
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.